Under pressure to rebuild as sales of its blockbuster Lantus slide, Sanofi desperately needed the launch of its Dengue vaccine to run smoothly. But it hasn’t. Analysts had expected blockbuster ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Derek Wallace was in a dengue-focused ICU in Thailand in ...

Sanofi is on course to launch the first vaccine against dengue fever, a mosquito-borne viral infection that threatens millions of the world's population, later this year.

A vaccine to prevent dengue fever discovered by a Saint Louis University researcher in 1997 and now licensed worldwide by Sanofi Pasteur has been approved for use in Mexico. Dengvaxia® is the world's ...

Climate change and mosquitos are creating an epidemic of dengue in Oaxaca, as researchers work to counteract the disease.

In 2015, the Philippines became the first Asian country to approve the sale of the world's first-ever dengue vaccine—Dengvaxia. However, a controversy arose in 2017 after manufacturer Sanofi ...

From the company's own site, we can see this pharma brand has a diversified portfolio of therapies across multiple clinical ...

Earlier, in the year 2016 WHO had recommended the usage of Sanofi's dengue vaccine to control Dengue. Sun Pharmaceutical Industries entered into an agreement with ICGEB to develop a novel dengue ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.